Beacon Investment Advisory Services Inc. Sells 146,154 Shares of DexCom, Inc. $DXCM

Key Points

• Beacon Investment Advisory Services Inc. sold 146,154 shares of DexCom, Inc., reducing its holdings by 29.7% and leaving it with approximately 345,590 shares, which now represent around 1.3% of its portfolio.
• DexCom recently reported earnings of $0.48 per share for the last quarter, exceeding the expected $0.45, and achieved a revenue of $1.16 billion, reflecting a year-over-year increase of 15.2%.
• Wall Street analysts have mixed views on DexCom, with ratings ranging from "Strong Buy" to "Market Perform," and a consensus target price of approximately $99.89 based on 14 buy ratings and three strong buy ratings.

Beacon Investment Advisory Services Inc. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 29.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 345,590 shares of the medical device company's stock after selling 146,154 shares during the period. DexCom accounts for approximately 1.3% of Beacon Investment Advisory Services Inc.'s holdings, making the stock its 22nd biggest position. Beacon Investment Advisory Services Inc. owned about 0.09% of DexCom worth $30,167,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of DXCM. Horizon Investments LLC grew its position in shares of DexCom by 2.2% during the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock valued at $383,000 after purchasing an additional 123 shares in the last quarter. Wedbush Securities Inc. grew its position in shares of DexCom by 1.2% during the first quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock valued at $899,000 after purchasing an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. grew its position in shares of DexCom by 3.2% during the first quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock valued at $407,000 after purchasing an additional 182 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. grew its position in shares of DexCom by 3.2% during the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company's stock valued at $411,000 after purchasing an additional 187 shares in the last quarter. Finally, Integrated Wealth Concepts LLC grew its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock valued at $227,000 after purchasing an additional 196 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Down 1.0%

Shares of NASDAQ DXCM opened at $67.50 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a market cap of $26.47 billion, a P/E ratio of 46.88, a PEG ratio of 1.43 and a beta of 1.48. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The firm has a 50-day simple moving average of $78.92 and a two-hundred day simple moving average of $78.05.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm's quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on DXCM shares. Oppenheimer lowered DexCom from an "outperform" rating to a "market perform" rating in a research report on Monday, September 8th. Morgan Stanley raised their price objective on DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Mizuho increased their price target on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $106.00 price target on shares of DexCom in a report on Friday, August 1st. Finally, Raymond James Financial increased their price target on shares of DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a report on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president owned 105,223 shares of the company's stock, valued at $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,849 shares of company stock worth $564,733 in the last ninety days. 0.32% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.